XML 22 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814
Acquisition (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 4 Months Ended 6 Months Ended
Jun. 24, 2015
Jun. 24, 2015
Aug. 29, 2015
Aug. 30, 2014
Jun. 24, 2015
Aug. 29, 2015
Aug. 30, 2014
Apr. 02, 2015
Feb. 28, 2015
Preliminary purchase price                  
Stock consideration           $ 240,907      
Preliminary purchase price allocation                  
Goodwill     $ 1,533,827     1,533,827     $ 76,124
Unaudited pro forma combined financial data                  
Bridge loan commitment fees incurred with the Acquisition by both the Company and EnvisionRx           15,375      
Net revenues     7,664,776 $ 6,522,584   14,312,337 $ 12,988,115    
Less pre-acquisition intercompany revenue     (23,777) (65,511)   (104,731) (131,413)    
Pro forma combined revenues     8,005,158 7,455,019   15,943,241 14,843,026    
Income before income taxes     37,932 147,709   69,209 201,036    
Net income     21,469 127,849   40,305 169,295    
Incremental interest expense on the 6.125% Notes issued on April 2, 2015       (28,852)   (11,097) (57,703)    
Incremental amortization resulting from fair value adjustments of the identifiable intangible assets     (3,778) (15,179)   (16,509) (26,530)    
Transaction expenses incurred by both the Company and EnvisionRx     36,754     55,864      
Debt extinguishment charges incurred by EnvisionRx     (33,205)     (33,205)      
Income tax benefit (expense) relating to pro forma adjustments     (3,294)     (5,966)      
Pro forma net income     $ 26,208 $ 87,285   $ 48,891 $ 92,414    
Basic income per share     $ 0.03 $ 0.09   $ 0.05 $ 0.09    
Diluted income per share     $ 0.02 $ 0.08   $ 0.05 $ 0.09    
6.125% senior notes due 2023                  
Acquisitions                  
Debt instrument, stated interest rate (as a percent)     6.125%     6.125%      
EnvisionRx                  
Acquisitions                  
Ownership interest (as a percent) 100.00% 100.00%     100.00%        
Stock consideration (in shares) 27,754                
Share price $ 8.68 $ 8.68     $ 8.68        
Preliminary purchase price                  
Cash consideration $ 1,883,405                
Stock consideration 240,907                
Total 2,124,312                
Preliminary purchase price allocation                  
Cash and cash equivalents 103,834 $ 103,834     $ 103,834        
Accounts receivable 900,473 900,473     900,473        
Inventories 7,276 7,276     7,276        
Deferred tax assets 516 516     516        
Prepaid expenses and other current assets 13,820 13,820     13,820        
Total current assets 1,025,919 1,025,919     1,025,919        
Property and equipment 13,196 13,196     13,196        
Intangible assets(1) 842,585 842,585     842,585        
Goodwill 1,457,703 1,457,703     1,457,703        
Other assets 8,919 8,919     8,919        
Total assets acquired 3,348,322 3,348,322     3,348,322        
Accounts payable 491,672 491,672     491,672        
Reinsurance funds held 381,225 381,225     381,225        
Other current liabilities(2) 207,723 207,723     207,723        
Total current liabilities 1,080,620 1,080,620     1,080,620        
Other long term liabilities(3) 143,390 143,390     143,390        
Total liabilities assumed 1,224,010 1,224,010     1,224,010        
Net assets acquired 2,124,312 2,124,312     2,124,312        
Amount due under the terms of agreement 116,500                
Acquisition costs     $ 9,613     $ 27,072      
EnvisionRx | Trademarks                  
Preliminary purchase price allocation                  
Estimated Fair Value of indefinite lived intangible assets 44,000                
EnvisionRx | Customer relationships                  
Preliminary purchase price allocation                  
Estimated Fair Value of Finite lived intangible assets $ 585,500                
Estimated Useful Life 17 years                
EnvisionRx | CMS license                  
Preliminary purchase price allocation                  
Estimated Fair Value of Finite lived intangible assets $ 108,000                
Estimated Useful Life 25 years                
EnvisionRx | Claims adjudication and other developed software                  
Preliminary purchase price allocation                  
Estimated Fair Value of Finite lived intangible assets $ 59,500                
Estimated Useful Life 7 years                
EnvisionRx | Trademarks                  
Preliminary purchase price allocation                  
Estimated Fair Value of Finite lived intangible assets $ 15,600                
Estimated Useful Life 10 years                
EnvisionRx | Backlog                  
Preliminary purchase price allocation                  
Estimated Fair Value of Finite lived intangible assets $ 12,500                
Estimated Useful Life 3 years                
EnvisionRx | Other                  
Preliminary purchase price allocation                  
Estimated Fair Value of Finite lived intangible assets $ 17,485                
Estimated Useful Life 5 years                
EnvisionRx | 6.125% senior notes due 2023                  
Acquisitions                  
Principal amount of debt               $ 1,800,000  
Debt instrument, stated interest rate (as a percent)     6.125%     6.125%   6.125%  
EnvisionRx                  
Unaudited pro forma combined financial data                  
Net revenues   364,159   $ 997,946 1,735,635   $ 1,986,324    
Income before income taxes   (56,544)   $ 3,467 (45,307)   $ 7,352    
Debt extinguishment charges incurred by EnvisionRx   $ 31,601     $ 31,601